These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 29973204)

  • 21. T-Cell Therapy Using Interleukin-21-Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression.
    Chapuis AG; Roberts IM; Thompson JA; Margolin KA; Bhatia S; Lee SM; Sloan HL; Lai IP; Farrar EA; Wagener F; Shibuya KC; Cao J; Wolchok JD; Greenberg PD; Yee C
    J Clin Oncol; 2016 Nov; 34(31):3787-3795. PubMed ID: 27269940
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab.
    Martens A; Wistuba-Hamprecht K; Yuan J; Postow MA; Wong P; Capone M; Madonna G; Khammari A; Schilling B; Sucker A; Schadendorf D; Martus P; Dreno B; Ascierto PA; Wolchok JD; Pawelec G; Garbe C; Weide B
    Clin Cancer Res; 2016 Oct; 22(19):4848-4858. PubMed ID: 27169993
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Pilot Trial of the Combination of Transgenic NY-ESO-1-reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab.
    Nowicki TS; Berent-Maoz B; Cheung-Lau G; Huang RR; Wang X; Tsoi J; Kaplan-Lefko P; Cabrera P; Tran J; Pang J; Macabali M; Garcilazo IP; Carretero IB; Kalbasi A; Cochran AJ; Grasso CS; Hu-Lieskovan S; Chmielowski B; Comin-Anduix B; Singh A; Ribas A
    Clin Cancer Res; 2019 Apr; 25(7):2096-2108. PubMed ID: 30573690
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma.
    Nicholaou T; Ebert LM; Davis ID; McArthur GA; Jackson H; Dimopoulos N; Tan B; Maraskovsky E; Miloradovic L; Hopkins W; Pan L; Venhaus R; Hoffman EW; Chen W; Cebon J
    Clin Cancer Res; 2009 Mar; 15(6):2166-73. PubMed ID: 19276262
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF.
    Fong L; Kwek SS; O'Brien S; Kavanagh B; McNeel DG; Weinberg V; Lin AM; Rosenberg J; Ryan CJ; Rini BI; Small EJ
    Cancer Res; 2009 Jan; 69(2):609-15. PubMed ID: 19147575
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CTLA4 Message Reflects Pathway Disruption in Monogenic Disorders and Under Therapeutic Blockade.
    Garcia-Perez JE; Baxter RM; Kong DS; Tobin R; McCarter M; Routes JM; Verbsky J; Jordan MB; Dutmer CM; Hsieh EWY
    Front Immunol; 2019; 10():998. PubMed ID: 31156616
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma.
    Slingluff CL; Zarour HM; Tawbi HA; Kirkwood JM; Postow MA; Friedlander P; Devoe CE; Gaughan EM; Mauldin IS; Olson WC; Smith KT; Macri MJ; Ricciardi T; Ryan A; Venhaus R; Wolchok JD
    Oncoimmunology; 2021 Mar; 10(1):1898105. PubMed ID: 33796406
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab.
    Martens A; Wistuba-Hamprecht K; Geukes Foppen M; Yuan J; Postow MA; Wong P; Romano E; Khammari A; Dreno B; Capone M; Ascierto PA; Di Giacomo AM; Maio M; Schilling B; Sucker A; Schadendorf D; Hassel JC; Eigentler TK; Martus P; Wolchok JD; Blank C; Pawelec G; Garbe C; Weide B
    Clin Cancer Res; 2016 Jun; 22(12):2908-18. PubMed ID: 26787752
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.
    Hannani D; Vétizou M; Enot D; Rusakiewicz S; Chaput N; Klatzmann D; Desbois M; Jacquelot N; Vimond N; Chouaib S; Mateus C; Allison JP; Ribas A; Wolchok JD; Yuan J; Wong P; Postow M; Mackiewicz A; Mackiewicz J; Schadendorff D; Jaeger D; Zörnig I; Hassel J; Korman AJ; Bahjat K; Maio M; Calabro L; Teng MW; Smyth MJ; Eggermont A; Robert C; Kroemer G; Zitvogel L
    Cell Res; 2015 Feb; 25(2):208-24. PubMed ID: 25582080
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3
    Sharma A; Subudhi SK; Blando J; Scutti J; Vence L; Wargo J; Allison JP; Ribas A; Sharma P
    Clin Cancer Res; 2019 Feb; 25(4):1233-1238. PubMed ID: 30054281
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical significance of plasmacytoid dendritic cells and myeloid-derived suppressor cells in melanoma.
    Chevolet I; Speeckaert R; Schreuer M; Neyns B; Krysko O; Bachert C; Van Gele M; van Geel N; Brochez L
    J Transl Med; 2015 Jan; 13():9. PubMed ID: 25592374
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interferon-γ Signaling in Melanocytes and Melanoma Cells Regulates Expression of CTLA-4.
    Mo X; Zhang H; Preston S; Martin K; Zhou B; Vadalia N; Gamero AM; Soboloff J; Tempera I; Zaidi MR
    Cancer Res; 2018 Jan; 78(2):436-450. PubMed ID: 29150430
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their Arginase1 production.
    Pico de Coaña Y; Poschke I; Gentilcore G; Mao Y; Nyström M; Hansson J; Masucci GV; Kiessling R
    Cancer Immunol Res; 2013 Sep; 1(3):158-62. PubMed ID: 24777678
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional
    Da Gama Duarte J; Parakh S; Andrews MC; Woods K; Pasam A; Tutuka C; Ostrouska S; Blackburn JM; Behren A; Cebon J
    Front Immunol; 2018; 9():411. PubMed ID: 29552014
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
    Iversen TZ
    Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A cancer vaccine induces expansion of NY-ESO-1-specific regulatory T cells in patients with advanced melanoma.
    Ebert LM; MacRaild SE; Zanker D; Davis ID; Cebon J; Chen W
    PLoS One; 2012; 7(10):e48424. PubMed ID: 23110239
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer.
    Twyman-Saint Victor C; Rech AJ; Maity A; Rengan R; Pauken KE; Stelekati E; Benci JL; Xu B; Dada H; Odorizzi PM; Herati RS; Mansfield KD; Patsch D; Amaravadi RK; Schuchter LM; Ishwaran H; Mick R; Pryma DA; Xu X; Feldman MD; Gangadhar TC; Hahn SM; Wherry EJ; Vonderheide RH; Minn AJ
    Nature; 2015 Apr; 520(7547):373-7. PubMed ID: 25754329
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Co-administration of RANKL and CTLA4 Antibodies Enhances Lymphocyte-Mediated Antitumor Immunity in Mice.
    Ahern E; Harjunpää H; Barkauskas D; Allen S; Takeda K; Yagita H; Wyld D; Dougall WC; Teng MWL; Smyth MJ
    Clin Cancer Res; 2017 Oct; 23(19):5789-5801. PubMed ID: 28634284
    [No Abstract]   [Full Text] [Related]  

  • 39. A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy.
    Du X; Tang F; Liu M; Su J; Zhang Y; Wu W; Devenport M; Lazarski CA; Zhang P; Wang X; Ye P; Wang C; Hwang E; Zhu T; Xu T; Zheng P; Liu Y
    Cell Res; 2018 Apr; 28(4):416-432. PubMed ID: 29472691
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ctla-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab?
    Ménard C; Ghiringhelli F; Roux S; Chaput N; Mateus C; Grohmann U; Caillat-Zucman S; Zitvogel L; Robert C
    Clin Cancer Res; 2008 Aug; 14(16):5242-9. PubMed ID: 18698043
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.